Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Instead, the company will focus on weight-loss ... known as just “Hims” at the time, as a platform for men to get ...

Hims is a telehealth company that offers a variety of online services tailored to men, including treatments for hair loss and erectile dysfunction, primary care, and more. Through the company ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

Hims & Hers' stock has seesawed wildly this year as its weight-loss business faces new pressures. Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...

Hims & Hers stock plummeted 26% after the FDA resolved the semaglutide shortage, impacting their compounded weight loss drug business. Hims & Hers faces a significant revenue risk, as the FDA’s ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections from ...